Managing Editor's Note: We're pleased to see more research and relief coming for people with autism and Asperger's because of this positive media report on oxytocin, despite the fact that the study only included 13 subjects, a low enough number to draw ridicule from the autism untreatables in other instances.
A point to ponder as we learn more, oxytocin is produced in the pituitary gland and this gland is affected by mercury exposure. From Britannica oxytocin is a ...hormone used clinically to stimulate contractions of the uterus during labour, to control bleeding following delivery, and to stimulate the secretion of breast milk. Oxytocin was first synthesized (along with the related vasopressin, or antidiuretic hormone [ADH]) by American biochemist Vincent du Vigneaud in 1953, and he received the Nobel Prize for Chemistry in 1955 for this work. Synthetic oxytocin has since become widely used in obstetric practice. Natural oxytocin is secreted by the posterior pituitary gland, which holds and secretes oxytocin produced by the hypothalamus.
In August of 2009, US News ran a story about a study from UCLA:The UCLA study found evidence linking inorganic mercury in the blood to tissues known to be targets for the toxin, such as the liver, the immune system and the pituitary gland.
From The Washington Post.
By Rob Stein
Washington Post Staff Writer
Tuesday, February 16, 2010
A nasal spray containing a hormone that is known to make women more maternal and men less shy apparently can help those with autism make eye contact and interact better with others, according to a provocative study released Monday.
The study, involving 13 adults with either a high-functioning form of autism or Asperger syndrome, a mild form of the disorder, found that when the subjects inhaled the hormone oxytocin, they scored significantly better on a test that involved recognizing faces and performed much better in a game that involved tossing a ball with others.
"This is the first study that looked at whether oxytocin has an effect on social behavior, which is a major deficit in autism," said Angela Sirigu, who directs the National Center for Scientific Research in France and led the study, published online by the Proceedings of the National Academy of Sciences. "It looks like it could be very helpful."
Researchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.
"I think it's going to be a very exciting finding for a lot of people," said Alex Martin, chief of cognitive neuropsychology at the National Institute of Mental Health.
Because oxytocin does not last long in the body and produces its effects for a relatively brief period, some experts said the findings were more likely to encourage drug companies to develop alternative substances that had the same benefits.
"This paper suggests that's worth doing," said Thomas R. Insel, director of the institute. "It adds another brick in the wall that suggests there may be an opportunity to develop treatment for one of the core symptoms of autism. That's been the brass ring."
But Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children. Administering the hormone soon after a child's autism is diagnosed might help him or her develop more normally, she said.
"It's possible it can become a cure, if it's given early when the problems are detected in the little kids," Sirigu said. "We can change the way these patients interact with people from childhood."
Because previous research has indicated that some people with autism might have abnormally low levels of oxytocin, conducting tests to identify those people and administering them the hormone might help as well, said Karen Parker, an assistant professor of psychiatry at Stanford University School of Medicine.
"If you can find someone who appears to have deficits in oxytocin biology, giving them what you might argue would be replacement oxytocin may be helpful," Parker said.
Autism is a baffling disorder that can cause a variety of symptoms, including speech and learning problems and profound, disabling difficulties understanding emotions and social cues when interacting with people. The number of children found to have autism has been increasing for reasons that remain mysterious.
Oxytocin is produced naturally in the bodies of humans and animals. It plays a key role in social interaction, promoting maternal behavior and monogamy in animals. The hormone also heightens social sensitivity, social awareness, generosity and trust in people.
Previous U.S. studies found that people with autism who received the hormone intravenously were less likely to engage in repetitive behavior that is another hallmark of autism and were more likely to be able to identify emotions in voices. Another study being published in the journal Biological Psychiatry found that 16 autistic males in Australia ages 12 to 19 who received the hormone through a nasal spray were better able to recognize other people's facial expressions.
"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism," said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.
While cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings. Oxytocin has been in use for several years as an "alternative" therapy for autism.
"Many families are using it with success and reporting improvement," said Wendy Fournier, president of the National Autism Association. "Getting double-blind clinical studies like this one published helps to bring credibility to parental reports."
"We need to be mindful of the fact that the majority of human studies of oxytocin have been conducted using adults, including this study, and only one paper has included individuals between the ages of 12 and 18. We have to be careful about the safety and efficacy of oxytocin on pediatric populations," said Clara Lajonchere, vice president of clinical programs for Autism Speaks.
The treatment category is sponsored by Lee Silsby, the leader in quality compounded medications for autism.